Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of CNTF (NT-501) for Macular Telangiectasia Type 2
NCT01949324Phase 2Completed
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Gene Editing, Gene Silencing, Device-based Delivery
- Countries
- 2
01
Overview
A Phase 2 trial of revakinagene taroretcel-lwey in macular telangiectasia type 2 (MacTel), sponsored by Neurotech Pharmaceuticals, Inc.. Started Apr 2014; status: completed.
02
Drugs
revakinagene taroretcel-lwey
03
Conditions
macular telangiectasia type 2 (MacTel)
Beyond the preview
Go deeper on NCT01949324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949324.